Our work to return AstraZeneca to growth and restore scientific leadership is underpinned by our continued commitment to driving business success responsibly.
2012: Our year in brief
Continued roll-out of our Access to Healthcare strategy to reach more patients through a range of different approaches. Read more
Disappointing ranking in latest Access to Medicines Index is informing a review of low performance areas. Read more
10 confirmed breaches of external sales and marketing codes, down from 17 in 2011, reflecting enhanced management oversight and compliance monitoring. Read more
Over 2,000 trials registered and results of more than 1,300 posted on public websites in line with our commitment to clinical trials transparency. Read more
We have reached over 250,000 young people in need through our Young Health Programme and are on track to meet our Clinton Global Initiative commitment to reach 500,000 by the end of 2015. Read more
Over 5,600 supplier risk assessments completed since the start of our assessment programme in 2009. Read more
AstraZeneca was once again listed in the Dow Jones Sustainability Index. We increased scores in some areas and lost ground in others. Read more